A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

At his home in Utah, Adrian wipes down all the surfaces in one room with isopropyl alcohol. He makes sure his HEPA filter is on. Next he snaps on a pair of nitrile gloves, then another, doubling up ...

Even more encouragingly, most people maintained the weight loss for the entire three-year study. “Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1, receptor agonist, has shown promise in promoting weight loss and improving ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the mechanisms of action of tirzepatide – a drug known as Zepbound™ – on weight ...